The FDA gave priority review to an application seeking approval of AXS-05 for Alzheimer's-related agitation, with a decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback